Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPV-specific cytotoxic T lymphocytes
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Vaccines & Immunotherapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HPV-specific cytotoxic T lymphocytes (HPV-CTLs) are a form of adoptive cell therapy used to treat HPV-associated cancers. These are T cells that specifically target human papillomavirus (HPV) antigens, particularly the E6 and E7 oncoproteins expressed by HPV-infected cancer cells. Upon infusion, these CTLs induce selective toxicity in HPV-positive cancer cells and other HPV-infected cells. Clinical trials have shown that HPV-CTLs can mediate durable, complete regression of metastatic cervical cancer in some patients, with ongoing responses observed for up to 18 months after treatment.
- Other names
- Allogeneic HPV-specific cytotoxic T lymphocytesHPV E6- and E7-specific cytotoxic T lymphocytes
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on HPV-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPV-specific cytotoxic T lymphocytes.